enGene Therapeutics (ENGN) Treasury Shares (2022 - 2026)

enGene Therapeutics (ENGN) posted quarterly Treasury Shares of $266025.0 for Q2 2026, down 2.53% quarter-over-quarter from $272925.0 in Q1 2026.

enGene Therapeutics (ENGN) Treasury Shares (2022 - 2026) Analysis & Trends

enGene Therapeutics (ENGN) has reported Treasury Shares for 3 consecutive years, with $266025.0 the latest figure, recorded in Q2 2026.

In Q2 2026, Treasury Shares changed N/A year-over-year to $266025.0; the TTM figure through Apr 2026 stood at $266025.0 (changed N/A YoY), while the FY2022 annual figure was $5.6 million, changed N/A from the prior year.
Treasury Shares slipped to $266025.0 in Q2 2026 per ENGN's latest filing, from $272925.0 in the prior quarter.
Across five years, Treasury Shares topped out at $5.6 million in Q4 2022 and bottomed at $266025.0 in Q2 2026.
Historically, Treasury Shares has averaged $2.9 million across 3 years, with a median of $2.9 million in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	2.72 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	8.96 Mn
10	enGene Therapeutics	124.11 Mn	124.11 Mn	-	-

Download Data